Business
Cancer Research UK Contract
Cancer Research UK Contract.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2317Z Angle PLC 25 May 2016 \n\nANGLE plc (\"the Company\")\n \nCANCER RESEARCH UK MANCHESTER INSTITUTE ADOPTS PARSORTIX FOR ROUTINE USE WITHIN CLINICAL TRIALS PORTFOLIO\n \nParsortix system already in 10 current clinical trials with a further 4 clinical trials at planning stage\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is delighted to announce that it has signed a contract with The University of Manchester, acting in this instance, through the Cancer Research UK Manchester Institute which will allow incorporation of ANGLE's Parsortix system in the Clinical and Experimental Pharmacology group for routine use in clinical trials and for research purposes.\n \nThe contract also provides for the continuation of the Clinical and Experimental Pharmacology group's work on the development and validation of new protocols demonstrating the system's utility for various applications in a variety of cancer types thereby enhancing the customer offering.\n \nUtilisation of the Parsortix system in clinical drug trials is a key part of ANGLE's strategy for commercialising Parsortix. Work by the Clinical and Experimental Pharmacology group to integrate the Parsortix system into clinical trial work flows will be key to ensuring wider adoption into a wide range of clinical trials.\n \nAs a result of the Clinical and Experimental Pharmacology group's successful evaluation of pre-clinical samples with the Parsortix system since 2012 and the strength of the technical and clinical data generated, Clinical and Experimental Pharmacology is now routinely using Parsortix as an epitope-independent technology for circulating tumour cell (CTC) capture and harvest.\n \nThe Parsortix system is currently being utilised by Clinical and Experimental Pharmacology in 10 clinical trials with an additional 4 trials in the planning stage. As a consequence of this inclusion, over 700 clinical samples have been processed and banked using established methods developed and published by the Clinical and Experimental Pharmacology group. \n \nThe Clinical and Experimental Pharmacology group believes that the ability to bank samples following a simple and rapid CTC enrichment using Parsortix is extremely valuable since it allows great flexibility for subsequent ...